How We Partner with Referring Providers

Helping your patients get relief from depression, anxiety, PTSD, and addiction.

What is Nushama?

Nushama provides IV ketamine and Spravato care to people seeking relief from mood disorders, in partnership with their mental health team.

Evidence-based medicine

IV ketamine treatments that are the gold standard and most well researched delivery mechanism for mood disorders
FDA-approved Spravato dosing protocols that are safe and effective for treatment-resistant depression (TRD) and suicidal ideation.
Quantitative and qualitative follow-ups before, after, and post-protocols.

Personalized Patient Care

Preparation & Integration included in all treatments to help your patient make sense of their experience.
Team of physicians, nurse practitioners, registered nurses, therapists, and medical assistants on site.
Unparalleled level of hospitality ensuring the patient always feels safe.

Collaboration

Careful patient screening by licensed mental health professionals.
Collaborative care with each patient’s mental health team.
An ecosystem of partners expanding access to the gold standard of care.

Working With Collaborating Clinicians

We believe IV ketamine and Spravato are complementary to, not a replacement for, a broader mental health plan. We aim to serve as a trusted extension of your services, by offering a safe, effective, fast-acting treatment for your patients struggling with mood disorders.

IV Ketamine vs. Spravato

This chart is designed to help referring providers understand the key differences between two treatment options offered at our center: IV Ketamine Infusion and Spravato (Esketamine Nasal Spray).

IV Ketamine Infusion

Spravato (Esketamine Nasal Spray)

Not covered by insurance (private pay)

Insurance Coverage

FDA-approved & covered by most insurances

Broader use: TRD, MDSI, PTSD, anxiety, existential distress

Indications

FDA-approved for: TRD (Treatment-Resistant Depression), MDSI (Major Depression with Suicidal Ideation)

Typically deeper, dissociative or psychedelic-like experiences

Depth of Experience

Mild to moderate dissociation; less immersive

6 infusions over 2–3 weeks (acute series); maintenance as needed every 1–6 months

Treatment Length

2 sessions/week for 4 weeks, then weekly or biweekly ongoing

Integrative: sessions include preparation and post-session integration

Treatment Model

Typically medication-only model without structured integration

Rapid—often within 1–3 infusions

Onset of Relief

Can be slower; benefits often emerge over several weeks

Private treatment room; monitored by medical provider

Setting

Administered in a clinical setting under supervision

$4,800 for initial series (not reimbursed)

Cost

Insurance copays & co-insurance (if applicable)

Refer a Patient to Nushama

Please fill out this HIPAA secure form. We will reach out to you and your patient about next steps.

Patient First Name

Patient Last Name

Date of Birth

Patient's Email Address

Patient's Phone Number

Referring Provider's First name

Provider's Last Name

Practice Name (if applicable)

Provider Phone Number

Provider Email Address

Is this email address HIPAA compliant?

Relevant Diagnosis for Treatment

Pertinent Clinical Information/Reason for Referral

Has the patient ever experienced psychotic symptoms?

Yes No

Did the patient give you permission to allow us to contact them directly?